Related Experiment Video

Updated: Mar 10, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.2K

Mechanistic insights into selective killing of OXPHOS-dependent cancer cells by arctigenin

Karin Brecht1, Virginie Riebel2, Philippe Couttet2

  • 1University Hospital Basel, Department of Biomedicine, Basel, Switzerland.

Toxicology in Vitro : an International Journal Published in Association with BIBRA
|December 8, 2016
PubMed

Insights

Arctigenin targets mitochondria in pancreatic cancer cells. It selectively kills oxidative phosphorylation-dependent cells by inhibiting mitochondrial complexes, leading to apoptosis and aponecrosis.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Oncology

Background:

  • Arctigenin shows potential as an anti-tumor treatment for advanced pancreatic cancer.
  • The precise mechanism by which arctigenin induces cancer cell death remains unclear.
  • Mitochondrial function is crucial in cancer cell metabolism and survival.

Purpose of the Study:

  • To elucidate the mechanism of arctigenin-induced toxicity in human pancreatic cancer cells (Panc-1).
  • To investigate the role of mitochondrial function, specifically oxidative phosphorylation (OXPHOS), in arctigenin's anti-cancer effects.
  • To compare arctigenin's mitochondrial toxicity with that of sorafenib, a known mitochondrial toxic anti-cancer drug.

Main Methods:

  • Cultured Panc-1 cells in glucose (glycolytic) versus galactose (OXPHOS-dependent) media.
  • Assessed arctigenin's effects on mitochondrial membrane potential and mitochondrial complexes II and IV.
  • Compared arctigenin's effects to sorafenib and analyzed downstream apoptotic markers.

Main Results:

  • Arctigenin dissipated mitochondrial membrane potential in both glycolytic and OXPHOS-dependent Panc-1 cells by inhibiting mitochondrial complexes II and IV.
  • Arctigenin selectively induced cell death in OXPHOS-dependent Panc-1 cells.
  • Selective cell killing was associated with endoplasmic reticulum (ER) stress, mitochondrial membrane permeabilization, and caspase activation, culminating in apoptosis and aponecrosis.

Conclusions:

  • Arctigenin exhibits selective toxicity towards OXPHOS-dependent pancreatic cancer cells.
  • The mechanism involves mitochondrial dysfunction, ER stress, and induction of apoptosis/aponecrosis.
  • Arctigenin's targeted action on OXPHOS-dependent cancer cells presents a potential therapeutic strategy for pancreatic cancer.
Keywords:
ArctigeninMitochondrial toxicityPanc-1Pancreatic cancerSorafenib

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

2.1K

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K